Get the content you want anytime you want.
REGISTER NOW | SIGN IN
The Best Infectious Disease News Delivered Weekly

The Contagion® C. Difficile specialty page provides c. difficile-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

C. DIFFICILE NEWS - Page 7

Top 5 <i>Contagion</i>® News Articles for the Week of March 19, 2017
In case you missed them, our top 5 articles for the week of March 19, 2017 are highlighted here.
UVC Machines Able to Reduce Transmission of 4 Major Superbugs in Hospitals
Duke Health researchers have found that a UVC machine use can reduce transmission of harmful superbugs in hospital settings.
Disinfectants and the Rise of the Resistant Bug
As emerging infectious diseases and resistant bugs become a growing issue, the need for stronger disinfectants becomes even more vital.
Beta-Lactam Allergy Linked to Worse Clinical Outcomes
On March 5, 2017, at the 2017 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), Gary Huang, MD, PhD, explained his research team's findings regarding self-reported allergy to drugs containing β-lactams.
Up-and-Coming Prevention Methods for <em>Clostridium difficile</em>
Robin Jump, MD, PhD, assistant professor in the Department of Medicine at the Case Western Reserve University sat down with Contagion™ to discuss up-and-coming prevention methods for C. diff in the hospital setting.
Vancomycin May Be More Effective for Treating Severe <em>C. diff</em> Infections
In a new study, researchers found that patients with severe Clostridium difficile (C. diff) infections who were treated with vancomycin had lower mortality rates than patients who were treated with metronidazole.
Reducing Antibiotics Cuts <i>C. difficile</i> rates
A new study from the United Kingdom highlights the importance of antibiotic restriction in the reduction of hospital-acquired C. difficile infections.
Pfizer's <i>C. difficile</i> Vaccine Succeeds in Phase II Study
Researchers found the experimental vaccine could potentially inhibit severe diarrhea and pseudomembranous colitis by inducing a functional antibody response that can neutralize the two main disease-causing toxins (toxin A or B) produced by C. difficile.
FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x